- Home
- KMI vs IMTXW Comparison
KMI vs IMTXW Comparison
Compare KMI & IMTXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMI
- IMTXW
- Stock Information
- Founded
- KMI 1936
- IMTXW N/A
- Country
- KMI United States
- IMTXW Germany
- Employees
- KMI N/A
- IMTXW 343
- Industry
- KMI Natural Gas Distribution
- IMTXW Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KMI Utilities
- IMTXW Health Care
- Exchange
- KMI Nasdaq
- IMTXW Nasdaq
- Market Cap
- KMI 52.4B
- IMTXW N/A
- IPO Year
- KMI 2011
- IMTXW N/A
- Fundamental
- Price
- KMI $24.82
- IMTXW $1.18
- Analyst Decision
- KMI Buy
- IMTXW
- Analyst Count
- KMI 13
- IMTXW 0
- Target Price
- KMI $24.92
- IMTXW N/A
- AVG Volume (30 Days)
- KMI 14.3M
- IMTXW N/A
- Earning Date
- KMI 10-16-2024
- IMTXW N/A
- Dividend Yield
- KMI 4.63%
- IMTXW N/A
- EPS Growth
- KMI 3.81
- IMTXW N/A
- EPS
- KMI 1.13
- IMTXW N/A
- Revenue
- KMI $15,151,000,000.00
- IMTXW N/A
- Revenue This Year
- KMI $3.78
- IMTXW N/A
- Revenue Next Year
- KMI $4.96
- IMTXW N/A
- P/E Ratio
- KMI $21.90
- IMTXW N/A
- Revenue Growth
- KMI N/A
- IMTXW N/A
- 52 Week Low
- KMI $15.91
- IMTXW N/A
- 52 Week High
- KMI $25.43
- IMTXW N/A
- Technical
- Relative Strength Index (RSI)
- KMI 74.01
- IMTXW N/A
- Support Level
- KMI $24.50
- IMTXW N/A
- Resistance Level
- KMI $25.01
- IMTXW N/A
- Average True Range (ATR)
- KMI 0.48
- IMTXW 0.00
- MACD
- KMI 0.06
- IMTXW 0.00
- Stochastic Oscillator
- KMI 76.89
- IMTXW 0.00
About KMI Kinder Morgan Inc.
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 82,000 miles in pipelines and 139 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
About IMTXW Immatics N.V.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.